Case Study: a pharma R&D planning group prioritizes the right indication with Evaluate

Indication Review and Prioritisation for a Pharma R&D Planning Group

The R&D Planning Group, a pharma R&D planning group, faced the challenge of having a limited budget to invest in a specific disease area. Their goal was to select an indication that offered the optimal balance of risk and commercial opportunity for development. To address this, they engaged the vendor Evaluate to assist with their portfolio prioritization.

Evaluate delivered a comprehensive analysis of the most attractive indications, evaluating key commercial and clinical attributes. This provided the client with the necessary insights to confidently define their target product profile and indication development roadmap, resulting in a well-informed and decisive investment decision.